MAR.F MARAVAI LIFESC.HLD.A -01

Healthcare Biotechnology Frankfurt Exchange
11.93 EUR
Close of Nov 12, 2026
2.42 7.80
Market cap
EUR 1.78B
P/E
-
P/B
5.91x
ROE
-20.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MAR.F undervalued?

Graham number

The Graham number of MARAVAI LIFESC.HLD.A -01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MARAVAI LIFESC.HLD.A -01 fundamental analysis

No fundamental analysis for MARAVAI LIFESC.HLD.A -01 yet.

MARAVAI LIFESC.HLD.A -01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MARAVAI LIFESC.HLD.A -01

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonu…

Full company profile